3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
4
Multiple Myeloma
3
Melanoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Small Cell Lung Carcinoma
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligometastatic Disease
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Promyelocytic, Acute
1
Leukemia
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Burkitt Lymphoma
1
Blast Crisis
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
pembrolizumab
21
lenvatinib
8
Paclitaxel
5
patritumab deruxtecan
3
enfortumab vedotin
2
belzutifan
2
Tretinoin
2
Surgical Procedures, Operative
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Capecitabine
2
tremelimumab
1
trametinib
1
poly ICLC
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
dabrafenib
1
Ramucirumab
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Pemetrexed
1
Levoleucovorin
1
Immunotherapy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Tretinoin
×
Clear all
NCT04303169
2025-10-27
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
146 enrolled
NCT04305041
2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
100 enrolled